PHARMACEUTICAL 2022

Lifecore Biomedical INC DE
Rank 309 of 471



PHARMACEUTICAL 2022

LANDEC

Lifecore Biomedical INC DE
Rank 309 of 471

The relative strengths and weaknesses of Lifecore Biomedical INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lifecore Biomedical INC DE compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 60% points.The greatest weakness of Lifecore Biomedical INC DE is the variable Stockholders Equity, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is 232%, being 43% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	148,321
Cost of Goods Sold	121,075
Intangible Assets	33,916
Liabilities, Current	101,888
Liabilities, Non-Current	167,772
Other Assets	200,401
Other Compr. Net Income	1,450
Other Expenses	14,006
Other Liabilities	30,480
Other Net Income	-24,047
Other Revenues	171,546
Property and Equipment	120,286
Research and Development	7,423
Selling, General and Administrative Expense	37,660

Output Variable	Value in 1000 USD
Assets	502,924
Liabilities	300,140
Expenses	180,164
Revenues	171,546
Stockholders Equity	202,784
Net Income	-32,665
Comprehensive Net Income	-31,940
BaseVar	590,136
ECR before LimitedLiability	102%
Economic Capital Ratio	232%